01:34 , Jun 22, 2018 |  BC Innovations  |  Targets & Mechanisms

T cell balancing act

Among the improvements to next-generation CAR T cell therapies is the need to optimize the ratios of the different T cell subsets. While CD8 + T cells have grabbed most of the attention, a study...
18:23 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Celldex reports Phase I/II data for varlilumab plus Opdivo in solid tumors

Celldex Therapeutics Inc. (NASDAQ:CLDX) reported data from 90 patients with advanced refractory solid tumors in a Phase I/II trial showing that varlilumab (CDX-1127) plus PD-1 inhibitor Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) was well...
18:29 , Apr 20, 2018 |  Clinical Results  |  Clinical Results

Celldex discontinues development of glembatumumab vedotin after TNBC failure

Celldex Therapeutics Inc. (NASDAQ:CLDX) said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb METRIC trial to treat metastatic triple-negative breast cancer (TNBC)...
19:11 , Apr 16, 2018 |  BC Extra  |  Clinical News

Celldex routed after TNBC failure

Celldex Therapeutics Inc. (NASDAQ:CLDX) fell $1.39 (65%) to $0.76 on Monday after it said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb...
01:21 , Jan 12, 2018 |  BC Innovations  |  Translation in Brief

In the twenties

A Cancer Cell study from University of Southampton and Celldex Therapeutics Inc. (NASDAQ:CLDX) researchers suggests combining CD27 agonists with tumor-targeting mAbs could help myeloid cells attack a broad array of cancers. The partners are testing...
23:25 , Jun 9, 2017 |  BioCentury  |  Finance

ASCO ascent

Investors were keenly focused on immunotherapy combinations containing PD-1/L1 and IDO inhibitors going into this year’s American Society of Clinical Oncology meeting, but the biggest gainers were companies that generated positive clinical data for other...
20:22 , Nov 4, 2016 |  BC Week In Review  |  Clinical News

Glembatumumab vedotin: Ph II data

Data from 62 patients with unresectable stage III or IV metastatic melanoma that has progressed after checkpoint inhibitor therapy in cohort 1 of an open-label, U.S. Phase II trial showed that IV glembatumumab vedotin every...
07:00 , Jul 14, 2016 |  BC Innovations  |  Product R&D

Apogenix's hex on TNF

TNF receptor superfamily members include well-validated cancer and immuno-oncology drug targets, but creating high-potency agonists is made difficult by the molecules' unique mode of ligand binding. Apogenix AG is designing compounds that more closely mimic...
07:00 , Jul 14, 2016 |  BC Innovations  |  Product R&D

Agonistic families

TNF superfamily receptors and their ligands have long been recognized as clinically relevant therapeutic targets for cancer, and dozens of companies are using different therapeutic modalities to target the proteins. Apogenix AG is one of...
07:00 , Oct 26, 2015 |  BioCentury  |  Strategy

Collaborating on combos

As oncologists and drug developers converge on the idea that combination therapies built on a backbone of PD-L1 or PD-1 inhibitors could lead to cures for some cancers, or keep them at bay for years,...